IDEXX Laboratories Inc. ($IDXX) Stock Forecast: Down 5.0% Today

What is IDEXX Laboratories Inc.?

IDEXX Laboratories, Inc. (IDXX) is a key player in the veterinary diagnostic lab market, benefiting from the rise in pet ownership and strong pet care spending. Today, the stock faced a decline despite recent positive developments and investor interest.

Why is IDEXX Laboratories Inc. going down?

IDXX stock is down 5.0% on Mar 6, 2026 15:07

• The introduction of InVue and the potential for recurring revenue growth highlighted IDXX's market strength. However, these advancements may not have fully countered the downward movement.
• Increased holdings by Victory Capital Management Inc. and New Age Alpha Advisors LLC reflect optimism in IDXX's future, indicating a favorable outlook.
• The stock's decline could be influenced by general market trends or profit-taking activities post recent performance, overshadowing the positive developments for IDXX.

IDXX Price Chart

IDXX Technical Analysis

IDXX News

Idexx Launch of InVue Provides Path to Recurring Revenue

Idexx Laboratories is poised for recurring revenue growth following the launch of its InVue product, further strengthening its position in the veterinary diagnostic lab market. The company benefits from increased pet ownership and owners' willingness to spend more on pet care. This aligns with a December 2025 report highlighting the InVue Cellular Analyzer's potential impact.

https://www.morningstar.com/company-reports/1450204-idexx-launch-of-invue-provides-path-to-recurring-revenue

IDEXX Laboratories, Inc. $IDXX Holdings Increased by Victory Capital Management Inc.

Victory Capital Management Inc. has increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.6% in the third quarter, now owning 198,562 shares valued at approximately $126.86 million. Other hedge funds, including Empowered Funds LLC, Sivia Capital Partners LLC, Arkadios Wealth Advisors, Bank of Montreal Can, and Bridgewater Advisors Inc., have also adjusted their positions in the company. Several analysts have updated their price targets and ratings, with the stock currently holding a "Moderate Buy" consensus and an average price target of $783.33.

https://www.marketbeat.com/instant-alerts/filing-idexx-laboratories-inc-idxx-holdings-increased-by-victory-capital-management-inc-2026-03-05/

Is Now a Good Moment to Include Labcorp Shares in Your Investment Portfolio?

Labcorp (LH) is poised for growth due to its expansion into high-potential testing fields like neurology and autoimmune disorders, strategic partnerships, and operational improvements from its LaunchPad initiative. Analysts have modestly raised earnings forecasts for 2026. However, the company faces headwinds from currency fluctuations and broader macroeconomic pressures, including inflation.

https://www.bitget.com/asia/news/detail/12560605237903

Chefs' Warehouse Breaks Below 200-Day Moving Average - Notable for CHEF

Shares of Chefs' Warehouse Inc (CHEF) fell below their 200-day moving average on Tuesday, trading as low as $60.20 per share and closing down about 6.8% for the day. The company's 200-day moving average was $62.78, indicating a potential bearish signal for investors. CHEF's 52-week trading range is $47.39 to $73.94.

https://www.nasdaq.com/articles/chefs-warehouse-breaks-below-200-day-moving-average-notable-chef-0

New Age Alpha Advisors LLC Increases Stock Position in IDEXX Laboratories, Inc. $IDXX

New Age Alpha Advisors LLC significantly increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10,065.0% in the third quarter, now owning 4,066 shares valued at $2.598 million. This comes amidst other institutional investors also modifying their holdings in the animal healthcare company. Additionally, recent insider selling by the CEO and a director was reported, while analysts maintain a "Moderate Buy" rating with an average target price of $783.33 for IDXX.

https://www.marketbeat.com/instant-alerts/filing-new-age-alpha-advisors-llc-increases-stock-position-in-idexx-laboratories-inc-idxx-2026-03-03/

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.3% Today

IDEXX Laboratories Inc. Price History

03.10.2025 - IDXX Stock was up 1.5%

• Expectations are high for IDEXX Laboratories' upcoming release of Q3 earnings, with analysts predicting an increase in quarterly earnings compared to the previous year. This optimistic forecast likely played a role in the recent bullish movement in the stock.
• Over the past decade, IDXX has demonstrated impressive long-term performance, consistently outperforming the market and delivering substantial returns for investors. This consistent track record could be attracting more interest from investors.
• A Hershey analyst's shift in sentiment towards IDEXX Laboratories, no longer holding a bearish view, combined with other top analyst upgrades, may be bolstering investor confidence in the company's future prospects and contributing to the current bullish trend in the stock.

03.10.2025 - IDXX Stock was up 0.1%

• IDXX stock witnessed a notable upturn today after announcing impressive Q3 earnings that surpassed expectations, along with an optimistic future forecast.
• The company disclosed adjusted earnings of $3.22 per share, marking a 15% year-over-year increase and exceeding analyst estimates.
• Analysts had predicted earnings of $3.14 per share, underscoring confidence in the company's ability to deliver robust financial results.
• Top Wall Street analysts have upgraded their outlook on IDXX, reflecting an increasing bullish sentiment among investors.

01.04.2025 - IDXX Stock was up 9.0%

• IDEXX Laboratories has showcased an average annual return of 21.28% over the past 10 years.
• The company boasts a market capitalization of $35.41 billion, indicating its market strength and resilience.
• Today, IDXX experienced a bullish movement likely attributed to its consistent growth and robust financial performance that has attracted investors seeking high returns.

05.02.2026 - IDXX Stock was down 5.1%

• IDXX experienced a bearish movement likely due to the overall challenges in the biotechnology sector as highlighted by an evaluation revision.
• The underperformance of a company and the broader sector may have raised concerns among investors, leading to a sell-off in IDXX.
• Market dynamics and performance challenges in the biotechnology sector could have contributed to the negative sentiment towards IDXX, resulting in the bearish movement.

05.02.2026 - IDXX Stock was down 5.3%

• The launch of the InVue product was expected to drive recurring revenue growth for IDEXX Laboratories. However, the market's reaction to significant stock selling by the CEO may have raised concerns among investors.
• The increased stake in IDXX by Victory Capital Management Inc. and New Age Alpha Advisors LLC could have been perceived positively. Still, substantial insider selling by the CEO may have overshadowed these moves, leading to a bearish sentiment.
• The CEO's sale of a significant amount of stock, mixed with missed EPS estimates in the recent earnings report, likely contributed to the bearish movement in IDXX's stock price today.
• The news of the stock falling below its 200-day moving average may have dampened the market sentiment towards IDXX, indicating a potential bearish signal and adding to the downward pressure on the stock price.

01.04.2025 - IDXX Stock was up 9.0%

• Strong Q1 earnings were reported by IDXX, surpassing expectations and resulting in an increased outlook for the fiscal year 2025. This positive financial performance has led to heightened investor interest and a rise in the stock price.
• Over the past decade, IDXX has consistently outperformed the market, achieving an impressive annualized return of 21.28%. This track record has likely fostered investor confidence in the company's future growth prospects.
• The notable financial results and a history of market-beating returns have fueled a positive trend in IDXX stock, reflecting optimistic investor attitudes and confidence in the company's future prospects.

04.07.2025 - IDXX Stock was up 4.2%

• IDEXX reported strong Q2 earnings, surpassing expectations with earnings of $3.50 per share and revenue reaching $1.11 billion.
• The impressive 11% growth in Companion Animal Group sales contributed to the revenue increase, showcasing the company's strong performance in its core business segment.
• The raised full-year EPS guidance and revenue forecast indicate a positive outlook for IDEXX, reassuring investors and justifying the premium valuation of the stock.
• Overall, the market responded positively to IDEXX's robust financial results and optimistic future prospects, driving the stock price higher.

21.10.2025 - IDXX Stock was up 5.0%

• IDXX stock experienced a strong bullish movement today, breaking out above the 20-day moving average, indicating positive momentum.
• The news about Molina (MOH) securing a deal to serve Florida's Medicaid members is unrelated to IDXX's bullish movement.
• Investors may have reacted positively to the breakout above the moving average, signaling potential upside for IDXX in the near term.
• The breakout could be a result of increased investor confidence in the company's growth prospects and continued demand for its veterinary diagnostic solutions.

06.02.2026 - IDXX Stock was down 5.0%

• The introduction of InVue and the potential for recurring revenue growth highlighted IDXX's market strength. However, these advancements may not have fully countered the downward movement.
• Increased holdings by Victory Capital Management Inc. and New Age Alpha Advisors LLC reflect optimism in IDXX's future, indicating a favorable outlook.
• The stock's decline could be influenced by general market trends or profit-taking activities post recent performance, overshadowing the positive developments for IDXX.

31.06.2025 - IDXX Stock was down 5.1%

• Despite high expectations for Q2 earnings with anticipated growth in various segments, IDXX experienced a strong bearish movement today.
• The market may have reacted negatively to the actual earnings release, which potentially fell short of the optimistic forecasts.
• Investors might have been disappointed by certain aspects of the earnings report, such as lower-than-expected revenue or guidance for future performance.
• It's possible that profit-taking or market dynamics unrelated to the company's fundamentals also contributed to the bearish movement in IDXX's stock price today.

02.01.2026 - IDXX Stock was down 1.7%

• Despite posting impressive Q4 earnings and revenue exceeding predictions, IDXX saw a downward trend in the market.
• A slight decline in stock price before the market opened may stem from heightened investor expectations, as the company emphasized robust pet health services and efficient cost control.
• Investors' varied responses could be linked to a marginal miss in earnings per share ($0.01) alongside revenue surpassing forecasts, leading to cautiousness among traders.
• IDXX's shares declining by 0.9% year-to-date, in contrast to the broader market's 1.4% gain (S&P 500), could have influenced the market downturn, with investors potentially anticipating more substantial growth despite the company's strong financial performance.

05.07.2025 - IDXX Stock was down 5.6%

• IDEXX Laboratories (IDXX) stock experienced a bearish movement despite surpassing earnings expectations and posting strong Q2 results.
• The market may have reacted negatively due to profit-taking by investors after a period of growth following the positive earnings report.
• Despite the positive news of revenue growth, EPS beat, and raised guidance, the stock might have been impacted by broader market trends or sector rotation.
• Investors might be cautious about the stock's valuation or potential future challenges despite the company's strong performance.